Forecast Period | 2025-2029 |
Market Size (2023) | USD 285.24 Million |
CAGR (2024-2029) | 4.75% |
Fastest Growing Segment | Sequencing by synthesis |
Largest Market | North America |
Market Size (2029) | USD 372.54 Million |
Market Overview
Global Microbiome Sequencing Service Market was
valued at USD 285.24 Million in 2023 and is expected to reach USD 372.54
Million by 2029 with a CAGR of 4.75% during the forecast period. The human
microbiome, the collection of microorganisms residing in and on the human body has
emerged as a crucial area of research with significant implications for health
and disease. Advances in microbiome sequencing have provided deeper insights
into how these microbial communities influence various aspects of health,
including digestion, immunity, and even mental well-being. This understanding
has fueled interest in microbiome analysis, driving demand for sequencing
services that can provide comprehensive and detailed microbiome profiles.
The growth of the microbiome sequencing service
market is significantly supported by technological advancements in sequencing
technologies. Next-Generation Sequencing (NGS) has revolutionized microbiome
research by offering high-throughput, cost-effective, and accurate sequencing
capabilities. This technology enables researchers and clinicians to analyze
complex microbial communities with unprecedented detail, facilitating the
identification of microbial species and their functional roles. Innovations in
bioinformatics tools and data analysis platforms further enhance the ability to
interpret vast amounts of sequencing data, contributing to the market's
expansion.
Microbiome sequencing services are increasingly
being utilized in healthcare to explore the link between microbiome composition
and various health conditions. Research indicates that imbalances in the
microbiome, known as dysbiosis, are associated with a range of diseases,
including inflammatory bowel disease (IBD), obesity, diabetes, and
cardiovascular disorders. Microbiome sequencing provides valuable insights into
these conditions, enabling the development of personalized treatment strategies
and probiotic interventions. The growing recognition of the microbiome’s role
in health and disease drives demand for sequencing services in clinical
research and diagnostics.
The consumer wellness sector is a burgeoning area
for microbiome sequencing services. Personalized microbiome testing kits allow
individuals to gain insights into their gut health, dietary impacts, and
potential areas for improvement. These consumer-facing products offer valuable
information for optimizing health and wellness, fueling interest and adoption.
As consumers become more proactive about their health, the demand for
microbiome testing services tailored to individual needs is expected to rise.
Significant investments in research and development
(R&D) are propelling the microbiome sequencing service market forward.
Academic institutions, research organizations, and pharmaceutical companies are
conducting extensive studies to explore the microbiome’s role in various
physiological processes and diseases. These research activities generate a
demand for sequencing services to support investigations into microbial
diversity, functional capabilities, and interactions with the host. Funding
from government agencies and private entities for microbiome-related research
further contributes to market growth.
The microbiome sequencing market is also influenced
by regulatory and ethical considerations. Governments and regulatory bodies are
establishing guidelines and standards for microbiome research and testing to
ensure data accuracy, privacy, and ethical use. Compliance with these
regulations is essential for market players to maintain credibility and ensure
the responsible use of microbiome data. Regulatory frameworks are evolving to
address the complexities of microbiome research, impacting the development and
implementation of sequencing services.
The future of the global microbiome sequencing
service market is promising, with continued advancements in sequencing
technologies, growing applications in healthcare and consumer wellness, and
increased investment in research. As the understanding of the microbiome’s
impact on health deepens, the demand for microbiome sequencing services is
expected to rise, driving market growth. The expansion of applications, coupled
with technological innovation and supportive regulatory frameworks, will play a
crucial role in shaping the future of the microbiome sequencing service market.
Key Market Drivers
Rising Prevalence of Chronic Diseases
Research has increasingly highlighted the critical
role that the microbiome—the diverse collection of microorganisms living in and
on the human body—plays in maintaining health and influencing disease outcomes.
Imbalances in the microbiome, known as dysbiosis, have been associated with a
range of chronic diseases. For instance, alterations in gut microbiota have
been linked to metabolic disorders like obesity and diabetes, as well as
inflammatory conditions such as inflammatory bowel disease (IBD) and
cardiovascular diseases. As the understanding of these connections deepens,
there is a growing demand for microbiome sequencing services to uncover the
underlying mechanisms and develop targeted interventions.
According to a 2022 report by the Australian Bureau
of Statistics, 81.4% of individuals reported having at least one long-term
health condition, with 49.9% having at least one chronic condition. The most
prevalent chronic conditions were mental and behavioral disorders (26.1%), back
problems (15.7%), and arthritis (14.5%).
The rising prevalence of chronic diseases is
driving advancements in microbiome sequencing technology. Next-Generation
Sequencing (NGS) has revolutionized the field by providing high-throughput,
accurate, and cost-effective methods for analyzing complex microbial
communities. These advancements enable researchers to perform detailed and
comprehensive microbiome profiling, which is essential for identifying disease-associated
microbial patterns and potential therapeutic targets. The growing need for such
detailed analyses in the context of chronic disease management is fueling the
demand for sophisticated microbiome sequencing services.
Microbiome sequencing offers valuable diagnostic
and therapeutic opportunities for chronic diseases. By identifying specific
microbial signatures associated with disease states, healthcare providers can
develop more accurate diagnostic tools and personalized treatment plans. For
example, understanding the gut microbiome’s role in diabetes can lead to
targeted dietary and probiotic interventions that help manage blood glucose
levels. Similarly, identifying microbial biomarkers for cardiovascular diseases
can aid in early detection and prevention. The potential to improve diagnostic
accuracy and therapeutic outcomes is a significant driver of the microbiome
sequencing service market.
The shift towards personalized medicine is another
factor driving the growth of the microbiome sequencing market. Personalized
medicine aims to tailor treatments based on an individual’s unique genetic and
microbial profile. Microbiome sequencing plays a critical role in this approach
by providing insights into how an individual’s microbiome influences disease risk
and treatment response. As personalized medicine gains traction, the demand for
microbiome sequencing services that support individualized health strategies is
expected to rise.
The rising prevalence of chronic diseases has led
to increased investment in research and development (R&D) focused on
understanding the microbiome’s role in health and disease. Government funding,
private investments, and academic research are driving innovation in microbiome
sequencing technologies and applications. This investment supports the
development of new sequencing methods, bioinformatics tools, and clinical
applications, further accelerating market growth.
As the clinical applications of microbiome
sequencing become more evident, its integration into routine healthcare
practices is increasing. Hospitals, research institutions, and diagnostic
laboratories are adopting microbiome sequencing to enhance disease management
and treatment efficacy. This integration into clinical workflows is a
significant factor contributing to the expansion of the microbiome sequencing
service market.
Increasing Research in Microbiome Science
Microbiome science, which studies the diverse
communities of microorganisms residing in and on the human body, as well as in
various environmental contexts, is uncovering new insights into the roles these
microorganisms play in health and disease. Research into the human microbiome
has revealed its critical impact on a range of physiological processes,
including metabolism, immunity, and mental health. This expanding knowledge
base is driving the demand for sophisticated microbiome sequencing services
that can provide detailed insights into microbial composition and function.
Recent breakthroughs in microbiome research have
demonstrated strong links between microbiome imbalances and conditions such as
obesity, diabetes, inflammatory bowel disease (IBD), and even neurodegenerative
disorders. These findings underscore the importance of understanding microbiome
dynamics and fuel the need for high-resolution sequencing technologies to
explore microbial communities in greater depth.
Since 2021, a diverse team of researchers at MIT
has been focused on translating new discoveries about the human microbiome into
treatments for various diseases. Alm’s lab, in collaboration with the Broad
Institute of MIT and Harvard, initially conducted pioneering work in
characterizing the gut microbiome and elucidating its connection to human
health. This foundational research has sparked a surge of interest in
microbiome studies, attracting scientists from diverse fields and catalyzing
new breakthroughs. Startups are now emerging to develop microbiome-based
therapies, while nonprofit organizations have also been established to help
translate these scientific advances into treatments that can benefit a broad
population.
The rapid advancement of sequencing technologies
has significantly contributed to the growth of the microbiome sequencing
market. Innovations such as next-generation sequencing (NGS), metagenomics, and
high-throughput sequencing have revolutionized microbiome research by providing
more detailed and accurate profiles of microbial communities. These
technologies enable researchers to analyze complex microbial ecosystems with
unprecedented precision, driving demand for advanced sequencing services.
For instance, NGS allows for the comprehensive
analysis of microbial DNA, revealing the presence and abundance of various
microorganisms within a sample. Metagenomics, on the other hand, provides
insights into the functional potential of microbial communities by sequencing
their collective genetic material. These technological advancements have
broadened the scope of microbiome research and increased the reliance on
sequencing services to generate actionable data.
The applications of microbiome research extend
beyond basic science into clinical and personalized medicine. Research into the
human microbiome is paving the way for novel diagnostic tools, targeted
therapies, and personalized health interventions. By understanding individual
microbiome profiles, healthcare providers can develop customized treatment
plans, improve disease management, and enhance overall patient outcomes.
The rise of personalized medicine, driven by
insights from microbiome research, has created a burgeoning demand for
microbiome sequencing services. These services are essential for identifying
specific microbial signatures associated with health conditions, monitoring
treatment responses, and tailoring interventions based on individual microbiome
characteristics.
Increased funding for microbiome research from
government agencies, research institutions, and private organizations has
significantly impacted the growth of the microbiome sequencing market. Grants
and investments support large-scale studies, clinical trials, and the
development of new sequencing technologies. Collaborative research efforts
between academic institutions, biotechnology companies, and healthcare
providers further drive the advancement of microbiome science and sequencing
services.
These collaborations facilitate the translation of
research findings into practical applications, creating a robust demand for
sequencing services that support ongoing studies and clinical innovations.
Download Free Sample Report
Key Market Challenges
Technical and Methodological Challenges
The global microbiome sequencing service market has
experienced significant growth due to increasing interest in understanding
microbial communities and their impact on health and disease. Despite its advancements,
the market faces substantial technical and methodological challenges that can
impact the accuracy, reliability, and overall effectiveness of microbiome
sequencing services.
One of the foremost technical challenges in
microbiome sequencing is ensuring the quality and integrity of samples.
Microbiome samples, which can be derived from diverse sources such as human
gut, skin, or environmental environments, are highly sensitive to
contamination. Even minor contamination can skew results and undermine the
reliability of data.
Contamination can occur at various stages, from
sample collection to processing and sequencing. Implementing stringent
protocols and quality control measures is essential to prevent contamination
and ensure that samples accurately represent the microbial communities of
interest. The development and adoption of improved sample handling and
processing techniques are critical to addressing this challenge.
The complexity of microbiome data poses a
significant challenge for both data management and interpretation. Microbiome
sequencing generates vast amounts of data, including information on microbial
diversity, abundance, and functional potential. Analyzing this data requires
sophisticated bioinformatics tools and expertise.
The diversity and variability within microbial
communities add layers of complexity to data interpretation. Accurate analysis
involves identifying and characterizing numerous microbial taxa and
understanding their interactions and roles within the ecosystem. This requires
advanced algorithms and computational resources to manage and make sense of the
extensive datasets produced by sequencing technologies.
The lack of standardization in microbiome
sequencing methodologies can lead to variability in results between different
studies and laboratories. Variations in protocols, such as differences in
sample preparation, sequencing techniques, and data analysis methods, can
affect the reproducibility and comparability of results.
Standardizing protocols and establishing best
practices are crucial for ensuring consistent and reliable outcomes across
different studies and settings. Industry-wide consensus on standardized
methodologies can help mitigate discrepancies and enhance the reproducibility
of microbiome research findings.
The management of large volumes of microbiome data
presents a significant challenge. Microbiome sequencing generates extensive
datasets that require robust storage solutions and efficient data management
systems. Ensuring that data is securely stored, easily accessible, and
organized in a way that facilitates analysis is essential for maintaining data
integrity and supporting ongoing research.
Advanced data storage solutions and integrated data
management platforms are necessary to handle the growing volume of microbiome
data. These systems must support the efficient processing and retrieval of data
while ensuring compliance with data privacy and security regulations.
Integrating microbiome data with other omics data,
such as genomics, proteomics, and metabolomics, can provide a more
comprehensive understanding of biological systems. However, combining data from
multiple sources introduces additional technical challenges, including data
harmonization, integration, and analysis.
Developing methodologies and tools to effectively
integrate and analyze multi-omics data is crucial for gaining deeper insights
into microbial functions and their interactions with host organisms. Addressing
these challenges requires advancements in analytical techniques and interdisciplinary
collaboration.
Interpreting microbiome sequencing results requires
expertise in microbial ecology and functional genomics. The relationship
between microbial composition and health outcomes is complex and not fully
understood. Researchers must navigate this complexity to extract meaningful
insights from the data and apply them to clinical or research contexts.
Enhanced training and education for researchers and
clinicians, along with the development of user-friendly analytical tools, can
support more accurate and insightful interpretation of microbiome data.
Collaborative efforts to advance the understanding of microbial functions and
their implications for health are also essential.
Key Market Trends
Growing Demand for Personalized Health Solutions
The global microbiome sequencing service market is
witnessing remarkable growth, largely driven by the increasing demand for
personalized health solutions. As individuals and healthcare providers alike
seek more tailored approaches to health management, microbiome sequencing has
emerged as a pivotal tool in delivering customized health insights.
Personalized health solutions, often referred to as
precision medicine, are designed to tailor medical care and wellness strategies
to the unique characteristics of each individual. This approach contrasts with
the traditional one-size-fits-all model by considering genetic, environmental,
and lifestyle factors to optimize health outcomes. The increasing consumer and
healthcare provider interest in personalized health is driving significant
growth in the microbiome sequencing service market.
Microbiome sequencing, the process of analyzing the
genetic material of microorganisms within a given environment, has become a
cornerstone of personalized health. The human microbiome, which consists of
trillions of microorganisms residing in and on the body, plays a crucial role
in overall health and disease susceptibility. By sequencing an individual’s
microbiome, healthcare providers can gain insights into microbial composition
and function, leading to more precise and effective health interventions.
One of the primary applications of microbiome
sequencing in personalized health is the development of customized nutritional
and lifestyle recommendations. Each individual’s microbiome composition affects
how they metabolize nutrients, respond to diets, and maintain gut health.
Sequencing provides detailed information on an individual’s microbiome profile,
allowing for tailored dietary advice and lifestyle changes that can enhance
health and prevent disease. For example, personalized nutrition plans based on
microbiome analysis can help optimize digestion, improve metabolic health, and
support weight management.
Microbiome sequencing is also facilitating the development
of targeted therapeutics and probiotics. By identifying specific microbial
imbalances or deficiencies, healthcare providers can prescribe targeted
probiotic supplements or other interventions designed to restore a healthy
microbiome balance. This personalized approach to therapy is more effective
than generalized treatments, as it addresses the root cause of imbalances
unique to each individual’s microbiome.
The ability to personalize health solutions extends
to disease prevention and management. Microbiome sequencing can identify
biomarkers associated with susceptibility to certain diseases, such as
inflammatory conditions, diabetes, and cardiovascular diseases. By
understanding an individual’s risk factors through their microbiome profile, preventive
measures and early interventions can be tailored accordingly. This proactive
approach helps in managing chronic conditions more effectively and reducing the
risk of disease progression.
The increasing consumer interest in personalized
health is a significant driver of growth in the microbiome sequencing service
market. Individuals are becoming more proactive about their health, seeking
personalized insights and solutions that align with their unique biological
profiles. Direct-to-consumer microbiome testing services are gaining
popularity, offering individuals the opportunity to explore their microbiome
data and make informed health decisions.
Direct-to-consumer microbiome testing services have
democratized access to personalized health insights. These services provide
individuals with easy-to-understand reports on their microbiome composition,
along with actionable recommendations for diet, lifestyle, and wellness. The
growing availability and affordability of such tests are expanding market reach
and driving consumer adoption.
The integration of microbiome sequencing with
digital health platforms is further fueling market growth. Mobile apps and
online platforms that analyze microbiome data and provide personalized health
recommendations are becoming increasingly prevalent. These platforms offer
users a convenient way to track their health, monitor changes, and receive
ongoing guidance based on their microbiome profiles.
Segmental Insights
Technology Insights
Based on Technology, Sequencing by synthesis (SBS) have
emerged as the fastest growing segment in the Global Microbiome Sequencing
Service Market in 2023. SBS technology, pioneered by companies like Illumina,
has revolutionized the field of DNA sequencing. It involves synthesizing a complementary
DNA strand from a template strand and incorporating labeled nucleotides that
emit a signal when added. This process allows for real-time detection of
nucleotide incorporation, providing highly accurate sequencing data. The
continuous improvements in SBS technology have enhanced its efficiency, speed,
and read length capabilities, making it a preferred choice for microbiome
sequencing.
One of the primary reasons for the widespread
adoption of SBS is its high accuracy and reliability. The technology's ability
to produce high-quality data with low error rates is crucial for microbiome
research, where precise identification of microbial species and their relative
abundances is essential. Accurate sequencing is particularly important in
studies aiming to uncover the links between microbial communities and human
health, as even small errors can lead to significant misinterpretations.
SBS has become increasingly cost-effective, making
it accessible to a broader range of researchers and institutions. The reduction
in sequencing costs has been driven by advancements in technology, increased
competition among sequencing providers, and economies of scale. As a result,
SBS offers an attractive balance of high performance and affordability,
enabling more extensive and in-depth microbiome studies within budget
constraints.
The versatility of SBS technology has contributed
to its rapid growth in the microbiome sequencing service market. SBS is used in
a wide range of applications, including clinical diagnostics, environmental
studies, agricultural research, and pharmaceutical development. In clinical
settings, SBS is employed to investigate the role of the microbiome in various
diseases, such as gastrointestinal disorders, metabolic conditions, and
infectious diseases. In agriculture, SBS helps in understanding soil
microbiomes and their impact on crop health and productivity. The broad
applicability of SBS has expanded its market reach and driven demand across
multiple sectors.
The integration of advanced bioinformatics tools
and software with SBS has further accelerated its adoption. These tools enable
efficient analysis and interpretation of the vast amounts of data generated by
SBS, providing researchers with actionable insights into microbial communities.
Enhanced data analysis capabilities facilitate the identification of
biomarkers, functional pathways, and microbial interactions, thereby advancing
our understanding of microbiomes and their implications for health and disease.
Strategic collaborations and partnerships between
sequencing technology providers, academic institutions, and research
organizations have also played a significant role in the growth of SBS. These
collaborations foster the development and optimization of SBS workflows,
promote knowledge sharing, and drive innovation. By working together,
stakeholders can address technical challenges, improve sequencing accuracy, and
expand the applications of SBS technology.
Application Insights
Based on Application, Autoimmune Disorder have
emerged as the dominating segment in the Global Microbiome Sequencing Service
Market during the forecast period. The human microbiome, comprising trillions
of microorganisms residing in and on our bodies, plays a crucial role in
maintaining immune homeostasis. Recent research has unveiled strong
associations between microbiome imbalances and the onset of autoimmune
disorders. Conditions such as rheumatoid arthritis, multiple sclerosis, lupus,
and type 1 diabetes have been linked to dysbiosis, a state of microbial
imbalance, which can trigger or exacerbate autoimmune responses.
This growing understanding has fueled interest in
microbiome sequencing as a tool to explore these connections. By analyzing the
composition and function of microbial communities in individuals with
autoimmune disorders, researchers aim to identify specific microbial signatures
associated with these conditions. This, in turn, drives the demand for
comprehensive microbiome sequencing services that can provide detailed and
accurate insights into microbial ecosystems.
The rapid advancement of sequencing technologies
has significantly enhanced our ability to study the microbiome in the context
of autoimmune diseases. Next-generation sequencing (NGS), metagenomics, and
other high-throughput sequencing methods allow for in-depth analysis of
microbial DNA, revealing the diversity and functional potential of microbial
communities. These technologies have revolutionized microbiome research,
providing researchers with the tools needed to investigate the complex
interactions between the microbiome and the immune system.
For example, NGS enables the identification of
microbial taxa that are either overrepresented or underrepresented in
individuals with autoimmune disorders compared to healthy controls.
Metagenomics provides insights into the metabolic pathways and functional
capabilities of these microbial communities, helping to elucidate their roles
in disease mechanisms. These advancements drive the demand for microbiome
sequencing services as researchers seek to uncover the underlying microbial
factors contributing to autoimmune diseases.
The rise of personalized medicine is another
significant driver of the microbiome sequencing service market in the context
of autoimmune disorders. Personalized medicine aims to tailor treatments based
on individual genetic, environmental, and microbial profiles. As our
understanding of the microbiome's influence on autoimmune diseases deepens,
there is growing interest in developing targeted therapies that address
specific microbial imbalances.
Microbiome sequencing is essential for identifying
microbial targets and developing personalized interventions. By analyzing an
individual's microbiome, healthcare providers can design tailored treatment
plans that modulate the microbiome to restore balance and reduce autoimmune
responses. This personalized approach not only improves treatment efficacy but
also minimizes adverse effects, driving the demand for microbiome sequencing
services.
The increasing prevalence of autoimmune disorders
has led to numerous clinical and research collaborations aimed at understanding
and treating these conditions. Partnerships between academic institutions,
healthcare providers, and biotechnology companies facilitate large-scale studies
and clinical trials that require extensive microbiome sequencing. These
collaborations drive innovation and accelerate the translation of research
findings into clinical practice.
For instance, large consortia focused on autoimmune
research often incorporate microbiome sequencing to investigate the role of
microbial communities in disease progression and treatment response. These
collaborative efforts enhance the demand for sequencing services, as they rely
on detailed microbial analyses to achieve their research objectives.
Download Free Sample Report
Regional Insights
Based on Region, North America have emerged as the
dominating region in the Global Microbiome Sequencing Service Market in 2023. North
America, particularly the United States and Canada, is home to some of the
world’s most advanced technological infrastructures in the field of life
sciences. The region boasts numerous state-of-the-art research facilities,
universities, and biotechnology companies that are at the forefront of
microbiome research and sequencing technology.
The presence of cutting-edge sequencing platforms
and high-throughput technologies enables rapid and accurate analysis of complex
microbiome samples. Leading companies such as Illumina, Thermo Fisher Scientific,
and others have their headquarters or major operations in North America,
further consolidating the region’s technological edge in the microbiome
sequencing market.
North America’s dominance is also driven by
significant investments in research and development (R&D). Federal
agencies, private companies, and academic institutions invest heavily in
microbiome research, aiming to explore the intricate relationships between
microbial communities and human health, agriculture, and environmental sustainability.
Government initiatives such as the National
Institutes of Health (NIH) in the United States provide substantial funding for
microbiome research projects. This financial support fosters innovation and
facilitates the development of new sequencing technologies, bioinformatics
tools, and analytical methodologies that enhance the capabilities of microbiome
sequencing services.
A robust regulatory environment in North America
supports the growth and adoption of microbiome sequencing services. Regulatory
bodies such as the U.S. Food and Drug Administration (FDA) and Health Canada
play a crucial role in ensuring the safety, efficacy, and reliability of
sequencing technologies and related applications.
The clear regulatory frameworks and guidelines
provided by these agencies help streamline the development and
commercialization of microbiome sequencing services. While the regulatory
landscape is stringent, it offers a structured pathway for the introduction of
new technologies and ensures high standards of quality and reliability, thereby
fostering confidence among stakeholders.
North America’s healthcare landscape is
increasingly oriented towards personalized medicine, which emphasizes tailored
treatment approaches based on individual genetic and microbiome profiles.
Microbiome sequencing plays a critical role in this paradigm by providing
insights into the composition and function of microbial communities that can
influence health and disease.
The integration of microbiome data with genomic and
other omics data enables the development of personalized treatment plans,
preventive strategies, and therapeutic interventions. This focus on
personalized medicine drives the demand for advanced microbiome sequencing
services and positions North America as a leader in this field.
Recent Development
- In February 2024, global testing leader ALS
launched its Gut Microbiome Sequencing service, providing researchers worldwide
with a comprehensive solution for obtaining detailed, publication-ready data on
the human and animal gut microbiome. This service ensures high data reliability
through high-resolution microbiome sequencing, allowing for accurate analysis
of both known and novel microbes, and precise differentiation of closely
related species. Utilizing cutting-edge nanopore-based sequencing technology,
the service can sequence entire microbial communities within the intestinal
ecosystem, revealing the taxonomic composition down to the genus and species
level.
- In April 2024, Microbiome Insights Inc., a global
leader in microbial sequencing and bioinformatic analysis, announced the launch
of its new long-read sequencing services for both amplicon and shotgun
metagenomics. Utilizing cutting-edge high-throughput sequencers, innovative
sequencing strategies, and advanced bioinformatics pipelines, this service is
ideal for academic, clinical, and industry researchers seeking breakthroughs in
microbial research. The long-read sequencing service at Microbiome Insights
adheres to a rigorous workflow, encompassing experimental design and sampling,
RNA extraction, library preparation, quality control, and bioinformatics
analysis. This new offering enables the analysis of microbial communities by
generating longer sequences, up to 4kb.
- In June 2023, Zymo Research, a prominent provider
of microbiology research tools, officially launched its Full-Length 16S
Sequencing Service. This service offers researchers high-quality, full-length
16S rRNA gene sequencing for microbiome analysis. The new full-length 16S
service enhances species resolution and data quality while remaining
cost-effective compared to traditional short-read 16S sequencing. Zymo Research
is utilizing the latest sequencing platforms by Pacific Biosciences (PacBio) to
deliver this advanced service.
Key Market Players
- Microbiome Insights
- BaseClear
BV
- Clinical
Microbiomics A/S
- Mérieux
NutriSciences Corporation
- MR DNA
(Molecular Research LP)
- Prescient
Medicine Holdings, Inc.
- Rancho
Biosciences LLC
- Second
Genome Inc.
- Zymo
Research Corporation
- uBiome,
Inc.
|
By
Technology
|
By Application
|
By Region
|
- Sequencing
by synthesis
- Sequencing
by ligation
- Sanger
sequencing
- Others
|
- Autoimmune
Disorder
- Cancer
- Gastrointestinal
Disorders
- Others
|
- North
America
- Europe
- Asia Pacific
- South
America
- Middle East
& Africa
|
Report Scope:
In this report, the Global Microbiome Sequencing
Service Market has been segmented into the following categories, in addition to
the industry trends which have also been detailed below:
- Microbiome Sequencing Service Market, By Technology:
o Sequencing by synthesis
o Sequencing by ligation
o Sanger sequencing
o Others
- Microbiome Sequencing Service Market, By Application:
o Autoimmune Disorder
o Cancer
o Gastrointestinal Disorders
o Others
- Microbiome Sequencing Service Market, By
Region:
o North America
§ United States
§ Canada
§ Mexico
o Europe
§ France
§ United Kingdom
§ Italy
§ Germany
§ Spain
o Asia Pacific
§ China
§ India
§ Japan
§ Australia
§ South Korea
o South America
§ Brazil
§ Argentina
§ Colombia
o Middle East & Africa
§ South Africa
§ Saudi Arabia
§ UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Microbiome
Sequencing Service Market.
Available Customizations:
Global Microbiome Sequencing Service Market report
with the given market data, Tech Sci Research offers customizations according
to a company's specific needs. The following customization options are
available for the report:
Company Information
- Detailed analysis and profiling of additional
market players (up to five).
Global Microbiome Sequencing Service Market is an
upcoming report to be released soon. If you wish an early delivery of this
report or want to confirm the date of release, please contact us at [email protected]